Cardiovascular Stents Market Size to Reach US$ 23.1 Bn by 2032 - Persistence Market Research Forecasts 8.9% CAGR

The global cardiovascular stents market is undergoing a pivotal transformation, driven by clinical innovation, healthcare policy shifts, and rising demand for minimally invasive cardiac procedures. The market, projected to be valued at US$ 12.7 Bn in 2025, is expected to reach US$ 23.1 Bn by 2032, reflecting an impressive CAGR of 8.9% over the forecast period, according to Persistence Market Research.

Growing incidence of cardiovascular diseases (CVDs), aging populations, and increasing accessibility to percutaneous coronary interventions (PCI) are fueling the expansion. Precision-engineered cardiovascular stents are now replacing traditional surgical interventions, offering targeted, efficient, and faster treatments for obstructed arteries. Among all types, coronary stents lead the market with an estimated 67.3% share in 2025, while North America dominates regionally due to high disease burden and rapid adoption of next-gen stent technologies.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35535

✅Key Highlights from the Report:

➤ Coronary stents projected to dominate with a 67.3% share in 2025
➤ Drug-eluting stents (DES) favored for superior patient outcomes and lower reintervention rates
➤ North America expected to lead the market, driven by aging demographics and advanced clinical adoption
➤ Dual-therapy stents combining antiproliferative and antithrombotic mechanisms are gaining investor attention
➤ Clinical trials targeting bifurcations and left main disease are expanding procedural indications
➤ Biodegradable polymers and nanocoatings are unlocking premium commercialization opportunities

✅Market Segmentation: By Procedure & Stent Type

The cardiovascular stents market can be broadly segmented by procedure type into coronary stenting and peripheral stenting. Coronary stenting, being the most prevalent, caters to patients with Coronary Artery Disease (CAD), a leading global health burden. Its minimally invasive nature, coupled with quicker recovery compared to bypass surgery, makes it the preferred choice, especially among older adults with comorbidities. Peripheral stenting is rapidly gaining attention, particularly due to the increasing prevalence of Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI) in diabetic and elderly populations.

In terms of stent types, the market includes Drug-Eluting Stents (DES), bare-metal stents, bioresorbable stents, and others. Among these, DES account for 65.2% of the market share as of 2025. Their clinical efficacy in reducing restenosis and repeat procedures drives preference among physicians. Bioresorbable stents, while still niche, are gaining popularity due to their ability to reduce long-term complications and preserve arterial flexibility-a benefit particularly valuable for younger patients or those at high risk of future interventions.

✅Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/cardiovascular-stents-market.asp

✅ Regional Insights

North America, particularly the U.S., leads the global cardiovascular stents market with a projected 30.6% market share in 2025. The region benefits from a combination of technological leadership, increasing PCI volumes, and favorable reimbursement policies. Rising adoption of robotic-assisted PCI, intravascular imaging (IVUS/OCT), and thin-strut DES further supports market maturity.

In Europe, despite the adoption of advanced imaging and stenting technologies-especially in Germany-the market is constrained by regulatory delays due to the European Union Medical Device Regulation (EU MDR). The regulatory backlog has impacted product availability and created headwinds for global companies seeking timely re-certification under the new guidelines.

✅ Market Drivers

The global burden of cardiovascular disease remains the central driver of stent demand. With over 9 million deaths annually attributed to ischemic heart disease, the push for accessible and effective interventions is stronger than ever. The rise of lifestyle-induced risk factors such as obesity, diabetes, and hypertension has amplified the need for minimally invasive procedures like stenting. Persistence Market Research reports that emerging economies, in particular, are aggressively scaling their interventional cardiology programs to meet rising demand.

Aging populations further fuel demand. In high-income countries, nearly 40% of individuals over 60 have heart conditions that may require stenting. As access to PCI improves in emerging markets, global stent use is expected to surge across both public and private healthcare systems.

✅ Market Restraints

Despite its advantages, cardiovascular stenting is not without risks. Bleeding complications, infections, and allergic reactions-especially in older patients or those with comorbid conditions-are leading restraints. An estimated 6-8% of PCI patients experience access-site complications such as hematoma or bleeding, which can lead to prolonged hospital stays or further complications. Furthermore, contrast-induced nephropathy caused by iodinated dyes presents a significant limitation in patients with renal impairment.

These concerns influence physician decisions and limit stent use among vulnerable patient cohorts. As stent placement is highly dependent on anatomical and systemic risk factors, any complication post-implantation can reduce trust in long-term efficacy-making continuous innovation and safety surveillance critical.

✅ Market Opportunities

Innovation remains a key opportunity driver. Research into ultra-thin strut DES, magnesium-based bioresorbable scaffolds, and targeted drug-release technologies is enabling access to previously underserved patient segments, such as those with small vessel disease or complex bifurcated lesions.

The MAGNITUDE trial, conducted in 2024, underscored the safety and efficacy of magnesium-based resorbable stents, showing reduced inflammatory responses and improved vessel healing. These advances make stents more suitable for younger patients or those requiring future interventions-markets traditionally underserved by metallic implants.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35535

✅ Reasons to Buy the Report:

✔ Gain in-depth insight into a fast-growing medical device sector with a projected CAGR of 8.9%
✔ Understand emerging trends in biodegradable stents and robotic PCI systems
✔ Analyze region-specific opportunities influenced by pricing regulations and clinical adoption
✔ Benchmark competitive strategies of leading companies such as Abbott, Boston Scientific, and Medtronic
✔ Access strategic recommendations grounded in real-world procedural data and regulatory shifts

✅Company Insights

The cardiovascular stents market is characterized by both global giants and specialized regional players focused on R&D and affordability. Leading players include:

✦ Abbott Laboratories
✦ Boston Scientific Corporation
✦ Medtronic plc
✦ Biotronik SE & Co. KG
✦ MicroPort Scientific Corporation
✦ B. Braun Melsungen AG
✦ Cardinal Health, Inc.
✦ C. R. Bard, Inc.
✦ Cook Medical
✦ Terumo Corporation

✅Recent Developments:

✦ In January 2025, Bentley launched the BeGraft stent graft system and BeFlared FEVAR system at the Leipzig Interventional Course, enhancing its endovascular portfolio.
✦ In May 2024, Abbott introduced its XIENCE Sierra stent system in India post-regulatory approval by the Central Drugs Standard Control Organization (CDSCO), tapping into the price-sensitive South Asian market.

✅Conclusion

The global cardiovascular stents market is not only expanding in volume but also transforming in depth-thanks to innovation in materials, delivery systems, and procedural imaging. With an increasing shift toward value-based healthcare, manufacturers are being compelled to invest in stents that combine safety, cost-efficiency, and improved patient outcomes.

According to Persistence Market Research, by 2032, the market is poised to grow to US$ 23.1 Bn, reflecting rising procedural volumes across both mature economies and fast-evolving healthcare ecosystems in Asia Pacific. While regulatory hurdles and safety concerns remain, the pace of R&D, particularly in drug-eluting and bioresorbable segments, continues to offer robust growth opportunities.

For investors, clinicians, and medical device firms alike, the cardiovascular stents market represents a critical area of opportunity-one shaped by innovation, access, and an urgent global need to address rising heart disease burdens.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.